GO:2000180 negative regulation of androgen biosynthetic process: Mechanism, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:2000180 describes any process that stops, prevents, or reduces the frequency, rate or extent of androgen biosynthetic process.
• Androgen biosynthesis is negatively regulated by feedback loops, including the PARP7-mediated ADP-ribosylation of androgen receptor, which promotes its degradation.
• Androgen deprivation therapy (ADT) is a clinical intervention that reduces androgen biosynthesis and is used in prostate cancer, but resistance can emerge via pathways such as AKT activation.
• The androgen-ILC2-dendritic cell axis in skin immunity demonstrates that negative regulation of androgen biosynthesis influences immune responses in a sexually dimorphic manner.
• Key genes involved in negative regulation include AR, PARP7, AKT1, and TMPRSS2:ERG fusion, which modulate androgen signaling and biosynthesis.
• CRISPR-based models (knockout, point mutation, knock-in, overexpression) are essential to dissect the causal roles of genes in this regulatory process.
Description
The Gene Ontology term GO:2000180, negative regulation of androgen biosynthetic process, refers to any biological process that stops, prevents, or reduces the frequency, rate or extent of androgen biosynthesis. Androgens, such as testosterone, are steroid hormones critical for male reproductive development, but they also influence diverse physiological systems, including immunity and brain function. Understanding how androgen production is negatively regulated is fundamental to endocrinology, oncology, and immunology. Dysregulation of this process is implicated in prostate cancer progression, where androgen deprivation therapies aim to suppress biosynthesis but often lead to resistance. Moreover, recent studies have uncovered a role for androgens in modulating immune cell crosstalk, highlighting the broad impact of this regulatory term. This article synthesizes current knowledge from authoritative QuickGO annotations and verified PubMed literature to provide a research-grade overview of GO:2000180, covering its definition, mechanisms, key genes, disease relevance, and experimental approaches.
negative regulation of androgen biosynthetic process At A Glance
| GO ID | GO:2000180 |
|---|---|
| GO term | negative regulation of androgen biosynthetic process |
| Ontology | biological_process |
| Synonym | negative regulation of androgen anabolism; negative regulation of androgen biosynthesis; negative regulation of androgen formation; negative regulation of androgen synthesis |
| Major function | Suppression of androgen production, impacting endocrine, immune, and reproductive physiology |
| Related processes | Androgen biosynthetic process (GO:0006702), regulation of androgen biosynthetic process (GO:2000179) |
| Clinical relevance | Prostate cancer, male contraception, immune sexual dimorphism |
| Key regulators | Androgen receptor (AR), PARP7, AKT1, TMPRSS2:ERG fusion |
What Is GO:2000180?
According to the Gene Ontology, GO:2000180 is defined as any process that stops, prevents, or reduces the frequency, rate or extent of androgen biosynthetic process. In other words, it encompasses molecular and cellular events that negatively regulate the production of androgens, such as testosterone and dihydrotestosterone. This regulation can occur at multiple levels, including transcriptional repression of steroidogenic enzymes, post-translational modification of the androgen receptor, or feedback inhibition by downstream signaling pathways.
Why Is negative regulation of androgen biosynthetic process Important in Cell Biology?
Negative regulation of androgen biosynthetic process is crucial for maintaining hormonal homeostasis and preventing excessive androgen signaling, which can drive pathologies such as prostate cancer and androgenetic alopecia. It also plays a role in male contraception strategies that rely on suppressing testosterone production. Furthermore, emerging evidence links androgen regulation to immune responses, as seen in the androgen-ILC2-dendritic cell axis that mediates sexual dimorphism in skin immunity. Therefore, deciphering the mechanisms of GO:2000180 offers insights into basic biology and therapeutic opportunities.
• Maintains endocrine balance by preventing overproduction of androgens.
• Key target in prostate cancer therapy, where androgen deprivation is a mainstay.
• Influences male fertility and is explored for male contraceptive development.
• Modulates immune cell function and sexual dimorphism in tissues like skin.
• Involved in brain function, including regulation of corticotropin-releasing factor receptor 1.
• Dysregulation can lead to androgen receptor-negative prostate cancer progression.
• Provides a model for feedback regulation in steroid hormone biosynthesis.
• Offers targets for CRISPR-based functional genomics to identify novel regulators.
• Relevant to understanding resistance to androgen-ablative therapies.
• Connects to metabolic pathways such as cholesterol biosynthesis in cancer cells.
What Happens During negative regulation of androgen biosynthetic process?
Feedback Inhibition by Androgen Receptor Signaling
In simple terms: When androgen levels are high, the body can turn down its own production to avoid excess.
The androgen receptor (AR) plays a central role in negative feedback. Upon binding androgens, AR translocates to the nucleus and modulates gene expression. One mechanism involves the ADP-ribosylation of AR by PARP7, which generates a degron that targets AR for degradation, thereby reducing androgen signaling and indirectly suppressing biosynthesis. This feedback loop helps maintain hormonal balance.
Post-Translational Modification and Degradation of AR
In simple terms: Chemical tags can mark the androgen receptor for destruction, lowering its activity.
PARP7 (also known as TIPARP) catalyzes ADP-ribosylation of AR, leading to its ubiquitination and proteasomal degradation. This post-translational modification is a key negative regulatory event that reduces AR availability, which in turn can decrease the expression of androgen biosynthetic enzymes under certain conditions.
Signaling Pathways That Suppress Androgen Synthesis
In simple terms: Other cellular signals can act as brakes on androgen production.
The PI3K/AKT pathway is frequently activated in prostate cancer and can promote resistance to androgen deprivation. However, AKT activation may also feed back to inhibit androgen biosynthesis under specific contexts. Additionally, the TMPRSS2:ERG fusion, common in prostate cancer, enhances AKT activation upon androgen deprivation, potentially altering negative regulation.
Transcriptional Repression of Steroidogenic Enzymes
In simple terms: The genes that make androgens can be switched off by repressors.
While specific transcriptional repressors of steroidogenic enzymes are not fully detailed in the provided citations, the general principle is that negative regulation can occur at the level of gene expression. For example, androgen-ablative therapies reduce androgen biosynthesis by suppressing the expression of enzymes like CYP17A1, although resistance mechanisms can emerge.
Key Genes Involved in GO:2000180 negative regulation of androgen biosynthetic process
The following genes and proteins are central to the negative regulation of androgen biosynthetic process, based on verified literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| AR | Androgen receptor; mediates feedback and is target of degradation | Central to androgen signaling and negative feedback |
| PARP7 | ADP-ribosylates AR, promoting its degradation | Key negative regulator of AR stability |
| AKT1 | Kinase involved in survival signaling; activated upon androgen deprivation | Linked to resistance to androgen-ablative therapies |
| TMPRSS2:ERG | Fusion gene common in prostate cancer; enhances AKT activation | Modifies response to androgen deprivation |
| CXCL8 | Chemokine induced by androgen-ablative therapies | Regulates cholesterol biosynthesis and supports AR-negative prostate cancer |
| mTORC1 | Kinase complex regulating metabolism | Mediates effects of CXCL8 on cholesterol biosynthesis |
| SREBP2 | Transcription factor controlling cholesterol synthesis | Downstream of mTORC1 in androgen-ablated cells |
| ILC2 | Group 2 innate lymphoid cells | Mediate androgen effects on skin immunity |
| Dendritic cells | Antigen-presenting cells | Part of androgen-ILC2-dendritic cell axis |
| CRFR1 | Corticotropin releasing factor receptor 1 | Regulated by androgens in the brain |
| PDE5 | Phosphodiesterase 5 | Androgen regulation studied but direct regulation unclear |
| PTPRR | Protein tyrosine phosphatase | Androgen-regulated, activates ERK1/2 in prostate cancer |
| CYP17A1 | Steroidogenic enzyme | Target of androgen deprivation therapy |
| HSD3B2 | Steroidogenic enzyme | Involved in androgen biosynthesis |
| SRD5A2 | 5-alpha reductase | Converts testosterone to DHT |
| StAR | Steroidogenic acute regulatory protein | Facilitates cholesterol transport for steroidogenesis |
| CYP11A1 | Cholesterol side-chain cleavage enzyme | First step in steroidogenesis |
| 3β-HSD | 3-beta-hydroxysteroid dehydrogenase | Catalyzes an early step in androgen synthesis |
How Is negative regulation of androgen biosynthetic process Regulated?
The negative regulation of androgen biosynthetic process is itself regulated by multiple mechanisms. The PARP7-AR axis exemplifies a feedback loop where AR activation induces PARP7, which then targets AR for degradation, thus dampening androgen signaling. Additionally, the PI3K/AKT pathway can be activated by androgen deprivation, and this activation may modulate negative regulation of biosynthesis, contributing to therapy resistance. In prostate cancer with TMPRSS2:ERG fusion, AKT activation is enhanced upon androgen deprivation, further complicating the regulatory landscape. These layers of regulation ensure tight control of androgen production but can be hijacked in disease.
negative regulation of androgen biosynthetic process and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| AR | Prostate cancer, androgen insensitivity | AR knockout or point-mutation cell lines |
| PARP7 | Prostate cancer, feedback regulation | PARP7 knockout or overexpression models |
| TMPRSS2:ERG | Prostate cancer fusion | Knock-in of fusion gene in prostate cells |
| CXCL8 | AR-negative prostate cancer | CXCL8 overexpression or knockout |
| AKT1 | Therapy resistance | AKT1 point-mutation knock-in |
Prostate Cancer
Prostate cancer is the most prominent disease linked to androgen biosynthesis. Androgen deprivation therapy (ADT) aims to suppress androgen production, but resistance often develops. For instance, androgen-ablative therapies can induce CXCL8, which regulates mTORC1/SREBP2-dependent cholesterol biosynthesis to support the progression of androgen receptor-negative prostate cancer cells. Moreover, in prostate cancer with TMPRSS2:ERG fusion, androgen deprivation leads to enhanced AKT activation, promoting survival. These findings highlight the clinical importance of understanding negative regulation of androgen biosynthesis.
Male Contraception
Suppression of androgen biosynthesis is a strategy for male contraception. Testosterone administration can inhibit gonadotropin secretion, thereby reducing endogenous androgen production and spermatogenesis. Understanding the negative regulation of androgen biosynthesis is therefore critical for developing reversible male contraceptives.
Immune Sexual Dimorphism
Androgens negatively regulate immune responses in a sexually dimorphic manner. A recent study identified an androgen-ILC2-dendritic cell axis in the skin, where androgens suppress ILC2 function and modulate dendritic cell activity, impacting immunity. This underscores the broader physiological relevance of GO:2000180 beyond reproduction.
Neurological and Metabolic Effects
Androgens regulate genes in the brain, such as corticotropin releasing factor receptor 1 (CRFR1), influencing stress responses. Additionally, androgen regulation of PTPRR activates ERK1/2 signaling in prostate cancer cells, linking to metabolic and proliferative pathways. These examples illustrate the diverse disease contexts where negative regulation of androgen biosynthesis plays a role.
From negative regulation of androgen biosynthetic process-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does PARP7 negatively regulate AR stability? | PARP7 knockout and overexpression cell lines |
| How does TMPRSS2:ERG affect AKT activation upon androgen deprivation? | Knock-in of TMPRSS2:ERG fusion in prostate cancer cells |
| What is the role of CXCL8 in cholesterol biosynthesis after ADT? | CXCL8 knockout or overexpression in AR-negative prostate cancer cells |
| Does androgen regulate CRFR1 in the brain? | Conditional AR knockout in mouse brain |
| Is PTPRR a direct target of androgen? | PTPRR promoter-reporter assays and AR ChIP |
| Can CRISPR screening identify novel negative regulators of androgen biosynthesis? | Genome-wide CRISPR knockout library in steroidogenic cells |
How to Study the negative regulation of androgen biosynthetic process Process
| Method | What It Measures | Typical Application |
|---|---|---|
| RNA-seq | Global gene expression changes | Identify transcriptional responses to androgen deprivation |
| Proteomics | Protein abundance and modifications | Detect AR ADP-ribosylation and degradation |
| CRISPR knockout screen | Gene essentiality and pathway regulators | Discover novel negative regulators of androgen biosynthesis |
| ChIP-seq | AR binding sites | Map AR occupancy on steroidogenic gene promoters |
| Luciferase reporter | Androgen receptor transcriptional activity | Test effects of candidate regulators |
| Western blot | Protein levels and phosphorylation | Validate AKT activation upon androgen deprivation |
| Immunofluorescence | Protein localization | Visualize AR nuclear translocation |
| ELISA | Androgen hormone levels | Measure testosterone production in cell culture media |
Transcriptomic Analysis (RNA-seq)
RNA sequencing can reveal changes in gene expression of steroidogenic enzymes and regulators upon modulation of candidate genes. For example, androgen deprivation alters the transcriptome, including induction of CXCL8.
Proteomic and Post-Translational Modification Studies
Mass spectrometry-based proteomics can identify ADP-ribosylation of AR by PARP7 and subsequent degradation. This approach is essential for understanding post-translational regulation.
CRISPR Screening
Genome-wide CRISPR knockout screens can identify genes whose loss affects androgen biosynthesis or AR signaling. Such screens are powerful for discovering novel negative regulators.
Reporter Assays and Imaging
Luciferase reporters driven by androgen-responsive promoters can measure AR activity. Imaging of fluorescently tagged AR can track its localization and degradation in live cells.
How CRISPR Can Be Used to Study GO:2000180 negative regulation of androgen biosynthetic process
Knockout
CRISPR knockout of candidate genes such as PARP7 or AR can reveal their roles in negative regulation of androgen biosynthesis. For instance, PARP7 knockout would stabilize AR, potentially altering feedback.
Point Mutation
Introducing point mutations in AR or PARP7 can dissect specific domains required for ADP-ribosylation or degradation, providing mechanistic insights.
Knock-in
Knock-in of the TMPRSS2:ERG fusion in prostate cancer cell lines can model its effect on AKT activation and androgen deprivation response.
Overexpression
Overexpression of CXCL8 or AKT1 can mimic conditions of therapy resistance and study their impact on cholesterol biosynthesis and androgen regulation.
How EDITGENE Supports negative regulation of androgen biosynthetic process Research
Researchers studying negative regulation of androgen biosynthetic process-related genes often need to determine whether a candidate gene is causally involved in suppressing androgen production or signaling. This requires precise genetic manipulation to avoid confounding effects. EDITGENE provides a comprehensive suite of CRISPR services to enable such investigations.
Contact EDITGENE today to design your custom CRISPR model for negative regulation of androgen biosynthetic process research.
Frequently Asked Questions About negative regulation of androgen biosynthetic process
What is GO:2000180?
GO:2000180 is the Gene Ontology term for negative regulation of androgen biosynthetic process, defined as any process that stops, prevents, or reduces the frequency, rate or extent of androgen biosynthesis.
What genes are involved in negative regulation of androgen biosynthetic process?
Key genes include AR, PARP7, AKT1, TMPRSS2:ERG, and CXCL8, which modulate androgen signaling and biosynthesis.
How does PARP7 regulate androgen biosynthesis?
PARP7 ADP-ribosylates the androgen receptor, marking it for degradation, thereby reducing androgen signaling and indirectly suppressing biosynthesis.
Why is negative regulation of androgen biosynthesis important in prostate cancer?
It is the basis for androgen deprivation therapy, but resistance can occur via pathways like AKT activation and CXCL8 induction.
What is the role of androgens in immunity?
Androgens negatively regulate immune responses, as shown by the androgen-ILC2-dendritic cell axis that mediates sexual dimorphism in skin immunity.
How can CRISPR be used to study this process?
CRISPR knockout, point mutation, knock-in, and overexpression models allow precise manipulation of candidate genes to test their roles in androgen regulation.
What are the synonyms for GO:2000180?
Synonyms include negative regulation of androgen anabolism, negative regulation of androgen biosynthesis, negative regulation of androgen formation, and negative regulation of androgen synthesis.
What diseases are linked to dysregulation of androgen biosynthesis?
Prostate cancer, male infertility, and immune disorders are associated with altered androgen regulation.
What methods are used to study negative regulation of androgen biosynthesis?
Methods include RNA-seq, proteomics, CRISPR screens, ChIP-seq, luciferase reporters, and ELISA for hormone measurement.
How does androgen deprivation affect cholesterol biosynthesis?
Androgen-ablative therapies induce CXCL8, which regulates mTORC1/SREBP2-dependent cholesterol biosynthesis to support AR-negative prostate cancer progression.
Conclusion
GO:2000180, negative regulation of androgen biosynthetic process, is a critical biological process with wide-ranging implications in endocrinology, oncology, and immunology. The interplay between AR, PARP7, AKT, and other regulators underscores the complexity of feedback mechanisms that control androgen production. Understanding these pathways is essential for developing therapies for prostate cancer and other androgen-related disorders. CRISPR-based models and advanced omics technologies will continue to drive discoveries in this field.
References
- 1. Chi L et al.. 2024. Sexual dimorphism in skin immunity is mediated by an androgen-ILC2-dendritic cell axis.. Science 384(6692):eadk6200 PMID: 38574174
- 2. Xiong X et al.. 2024. Androgen-ablative therapies inducing CXCL8 regulates mTORC1/SREBP2-dependent cholesterol biosynthesis to support progression of androgen receptor negative prostate cancer cells.. Oncogene 43(47):3456-3468 PMID: 39369166
- 3. Ma F et al.. 2025. Androgen deprivation-mediated activation of AKT is enhanced in prostate cancer with TMPRSS2:ERG fusion.. J Clin Invest 135(23) PMID: 41321318
- 4. Thirumalai A et al.. 2024. Testosterone and male contraception.. Curr Opin Endocrinol Diabetes Obes 31(6):236-242 PMID: 39155802
- 5. Rybka KA et al.. 2022. Androgen Regulation of Corticotropin Releasing Factor Receptor 1 in the Mouse Brain.. Neuroscience 491:185-199 PMID: 35398506
- 6. Wierbiłowicz K et al.. 2025. Parp7 generates an ADP-ribosyl degron that controls negative feedback of androgen signaling.. EMBO J 44(17):4720-4744 PMID: 40681873
- 7. Lin CS et al.. 2013. Direct androgen regulation of PDE5 gene or the lack thereof.. Int J Impot Res 25(3):81-5 PMID: 23486196
- 8. Munkley J et al.. 2015. Androgen-regulation of the protein tyrosine phosphatase PTPRR activates ERK1/2 signalling in prostate cancer cells.. BMC Cancer 15:9 PMID: 25592066
